Studies of muscarinic neurotransmission with antimuscarinic toxins

Progress in Brain Research

Volumn 145, Issue , 2004, Pages 121-128

  Potter, Lincoln T ^a   Flynn, Donna D ^a   Liang, Jing Sheng ^a   McCollum, Mark H ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Acetylcholine; Dendritic spines; Muscarinic receptors; Striatum; Toxin

Indexed keywords

BIOTIN; MUSCARINIC M1 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; RADIOACTIVE IODINE; SNAKE VENOM;

BRAIN CORTEX; CONFERENCE PAPER; CORPUS STRIATUM; EXTRACELLULAR SPACE; GLOBUS PALLIDUS; HIPPOCAMPUS; HUMAN; MOTOR CORTEX; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PUTAMEN; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; THALAMUS;

EID: 0344010037     PISSN: 00796123     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6123(03)45008-5     Document Type: Conference Paper

References (53)

1. 1 muscarinic mutant mice. Nature Neurosci., 6: 51-58.
2. Barnes, C.A., Meltzer, J., Houston, F., Orr, G., McGann, K. and Wenk, G.L. (2000) Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience, 99: 17-23.
3. Bernard, V., Levey, A.I. and Bloch, B. (1999) Regulation of the subcellular distribution of m4 muscarinic acetylcholine receptors in striatal neurons in vivo by the cholinergic environment: evidence for regulation of cell surface receptors by endogenous and exogenous stimulation. J. Neurosci., 19: 10237-10249.
4. Bourne, J.A. (2001) SCH 23390: the first selective D(1)-like receptor antagonist. CNS Drug Rev. Winter, 7: 399-414.
5. Chase, T.N., Oh, J.D. and Blanchet, P.J. (1998) Neostriatal mechanisms in Parkinson's disease. Neurology, 51(Suppl. 1): S30-S35.
6. Cuevas, J. and Adams, D.J. (1997) M4 muscarinic receptor activation modulates calcium channel currents in rat intracardiac neurons. J. Neurophysiol., 78: 1903-1912.
7. Cuevas, J., Harper, A.A., Trequattrini, C. and Adams, D.J. (1997) Passive and active membrane properties of isolated rat intracardiac neurons: regulation by H- and M-currents. J. Neurophysiol., 78: 1890-1902.
8. Dani, J.A. (2001) Overview of nicotinic receptors and their roles in the central nervous system. Biol. Psychiatry, 49: 166-174.
9. Dawson, T.M., Dawson, V.L., Gage, F.H., Fisher, L.J., Hunt, M.A. and Wamsley, J.K. (1991) Downregulation of muscarinic receptors in the rat caudate-putamen after lesioning of the ipsilateral nigrostriatal dopamine pathway with 6-hydroxydopamine: normalization by fetal mesencephalic transplants. Brain Res., 540: 145-152.
10. Fahn, S., Burke, R. and Stern, Y. (1990) Antimuscarinic drugs in the treatment of movement disorders. Prog. Brain Res., 84: 389-397.
11. Gerber, D.J., Sotnikova, T.D., Gainetdinov, R.R., Huang, S.Y., Caron, M.G. and Tonegawa, S. (2001) Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proc. Nat. Acad. Sci. USA, 98: 15312-15317.
12. Gomeza, J., Zhang, L., Kostenis, E., Felder, C., Bymaster, F., Brodkin, J., Shannon, H., Xia, B., Deng, C., Wess, J. (1999) Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M4 muscarinic acetylcholine receptor knockout mice. Proc. Nat. Acad. Sci. USA, 96: 10483-10488.
13. Graybiel, A.M. and Ragsdale, C.W., Jr. (1993) Biochemical anatomy of the striatum. In: P.C. Emson (Ed.), Chemical Neuroanatomy. Raven Press, NY, pp. 427-504.
14. Graybiel, A.M., Canales, J.J. and Capper-Loup, C. (2000) Levodopa-induced dyskinesias and dopamine-dependent stereotypies: a new hypothesis. Trends Neurosci., 23(Suppl. 10): S71-S77.
15. Gutierrez-Ford, C. and Potter, L.T. (2002) Role of striatal muscarinic receptors in pilocarpine-induced seizures. Soc. Neurosci. Abstr., 27: 912.7.
16. Hamilton, S.E., Loose, M.D., Qi, M., Levey, A.I., Hille, B., McKnight, G.S., Idzerda, R.L. and Nathanson, N.M. (1997) Disruption of the m1 receptor gene ablates muscarinic receptor-dependent M current regulation and seizure activity in mice. Proc. Nat. Acad. Sci. USA, 94: 13311-13316.
17. Harrison, M.B., Tissot, M. and Wiley, R.G. (1996) Expression of m1 and m4 muscarinic receptor mRNA in the striatum following a selective lesion of striatonigral neurons. Brain Res., 734: 323-326.
18. Hersch, S.M., Gutekunst, C.A., Rees, H.D., Heilman, C.J. and Levey, A.I. (1994) Distribution of m1-m4 muscarinic receptor proteins in the rat striatum: light and electron microscopic immunocytochemistry using subtype-specific antibodies. J. Neurosci., 14: 3351-3363.
19. Hersch, S.M., Ciliax, B.J., Gutekunst, C.A., Rees, H.D., Heilman, C.J., Yung, K.K., Bolam, J.P., Ince, E., Yi, H., Levey, A.I. (1995) Electron microscopic analysis of D1 and D2 dopamine receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferents. J. Neurosci., 15: 5222-5237.
20. Ingham, C.A., Hood, S.H., Taggart, P. and Arbuthnott, G.W. (1998) Plasticity of synapses in the rat neostriatum after unilateral lesion of the nigrostriatal dopaminergic pathway. J. Neurosci., 18: 4732-4743.
21. Kelton, M.C., Kahn, H.J., Conrath, C.L. and Newhouse, P.A. (2000) The effects of nicotine on Parkinson's disease. Brain Cogn., 43: 274-282.
22. Krajewski, J.L., Dickerson, I.M. and Potter, L.T. (2001) Site-directed mutagenesis of m1-toxin1: two residues responsible for high affinity binding to M1 muscarinic receptors. Mol. Pharmacol., 60: 725-731.
23. Levey, A.I. (1993) Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci., 52: 441-448.
24. Levin, E.D. and Rezvani, A.H. (2000) Development of nicotinic drug therapy for cognitive disorders. Eur. J. Pharmacol., 393: 141-146.
25. Liang, J.S., Santiago, M.P. and Potter, L.T. (2001) Sustained unilateral blockade of rat striatal M1 muscarinic receptors with m1-toxin, in vivo. Brain Res., 921: 211-218.
26. Louis, M. and Clarke, P.B. (1998) Effect of ventral tegmental 6-hydroxydopamine lesions on the locomotor stimulant action of nicotine in rats. Neuropharmacology, 37: 1503-1513.
27. Marino, M., Rouse, S.T., Levey, A.I., Potter, L.T. and Conn, P.J. (1998) Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-D-aspartate (NMDA) receptor currents in hippocampal pyramidal cells. Proc. Nat. Acad. Sci. USA, 95: 11465-11470.
28. Max, S.I., Liang, J.S. and Potter, L.T. (1993) Stable allosteric binding of m1-toxin to m1 muscarinic receptors. Mol. Pharmacol., 44: 1171-1175.
29. McCollum, M.H., Flynn, D.D. and Potter, L.T. (2001) Biotinylated m1-toxin. Soc. Neurosci. Abstr., 27: 810.16.
30. 1 muscarinic receptors. Soc. Neurosci. Abstr. 29: in press.
31. McGehee, D.S. and Role, L.W. (1995) Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Ann. Rev. Physiol., 57: 521-546.
32. Minic, J., Molgo, J., Karlsson, E. and Krejci, E. (2002) Regulation of acetylcholine release by muscarinic receptors at the mouse neuromuscular junction depends on the activity of acetylcholinesterase. Eur. J. Neurosci., 15: 439-448.
33. Miyakawa, T., Yamada, M., Duttaroy, A. and Wess, J. (2001) Hyperactivity and intact hippocampus-dependent learning in mice lacking the M1 muscarinic acetylcholine receptor. J. Neurosci., 15: 5239-5250.
34. 1 muscarinic receptors. Biochem. Biophys. Res. Comm., 271: 435-439.
35. Potter, L.T. (2001) Snake toxins that bind specifically to individual subtypes of muscarinic receptors. Life Sci., 68: 2541-2547.
36. Potter, L.T. and Purkerson, S.L. (1995) Pharmacology of striatal muscarinic receptors. In: M. Ariano and J. Surmeier (Eds.), Molecular and Cellular Mechanisms of Neostriatal Function. R.G. Landes Co., New York, pp. 241-254.
37. Potter, L.T., Krajewski, J.L. and Dickerson, I.M. (1997) Cloning and expression of the cDNA for an m1-toxin. Life Sci., 60: 1205.
38. Purkerson, S.L. and Potter, L.T. (1998) Use of antimuscarinic toxins to facilitate studies of striatal m4 muscarinic receptors. J. Pharmacol., 284: 707-713.
39. Rouse, S.T., Marino, M.J., Potter, L.T., Conn, P.J. and Levey, A.I. (1999) Muscarinic receptor subtypes involved in hippocampal circuits. Life Sci., 64: 501-509.
40. Santiago, M.P. and Potter, L.T. (2001) Biotinylated m4-toxin demonstrates more M4 muscarinic receptor protein on direct than indirect striatal projection neurons. Brain Res., 894: 12-20.
41. Schallert, T. and Tillerson, J.L. (1999) Development of behavioral outcome measures for preclinical Parkinson's research. In: D.F. Emerlich, R.L. Dean and P.R. Sanberg (Eds.), Central Nervous System Diseases. Innovative Animal Models from Lab to Clinic. Humana Press, Inc, Clifton, NJ, pp. 131-169.
42. Sharples, C.G., Kaiser, S., Soliakov, L., Marks, M.J., Collins, A.C., Washburn, M., Wright, E., Spencer, J.A., Gallagher, T., Whiteaker, P. and Wonnacott, S. (2000) UB-165: a novel nicotinic agonist with subtype selectivity implicates the alpha4beta2 subtype in the modulation of dopamine release from rat striatal synaptosomes. J. Neurosci., 20: 2783-2791.
43. Simon, N., Mouchet, J. and Bruguerolle, B. (2000) Effects of seven-day continuous infusion of L-DOPA on daily rhythms in the rat. Eur. J. Pharmacol., 401: 79-83.
44. Smith, Y., Bevan, M.D., Shink, B. and Bolam, J.P. (1998) Microcircuitry of the direct and indirect pathways of the basal ganglia. Neuroscience, 86: 353-387.
45. Smith, D.A. and Bolam, J.P. (1990) The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones. Trends Neurol. Sci., 13: 259-2265.
46. Spalding, T.A., Trotter, C., Skjaerbaek, N., Messier, T.L., Currier, E.A., Burstein, E.S., Li, D., Hacksell, U. and Brann, M.R. (2002) Discovery of an ectopic activation site on the M1 muscarinic receptor. Mol. Pharmacol., 61: 1297-1302.
47. Turski, L., Ikonomidou, C., Turski, W.A., Bortolotto, C.A. and Cavalheiro, E.A. (1989) Review: cholinergic mechanisms and epileptogenesis. The seizures produced by pilocarpine: a novel experimental model of intractable epilepsy. Synapse, 2: 154-171.
48. Ungerstedt, U. (1976) 6-Hydroxydopamine-induced degeneration of the nigrostriatal dopamine pathway: the turning syndrome. Pharmacol. Ther., 2: 37-40.
49. Wall, S.J., Yasuda, R.P., Li, M., Ciesla, W. and Wolfe, B.B. (1992) Differential regulation of subtypes m1-m5 muscarinic receptors in forebrain by chronic atropine administration. J. Pharmacol., 262: 584-588.
50. Watts, R.L. (1997) The role of dopamine agonists in early Parkinson's disease. Neurology, 49(Suppl 1): S34-S48.
51. Wichmann, T. and DeLong, M.R. (1998) Models of basal ganglia function and pathophysiology of movement disorders. Neurosurg. Clin. N. Amer., 9: 223-236.
52. Wonnacott, S., Kaiser, S., Mogg, Soliakov, A.L. and Jones, I.W. (2000) Presynaptic nicotinic receptors modulating dopamine release in the rat striatum. Eur. J. Pharmacol., 393: 51-58.
53. Zhang, W., Basile, A.S., Gomeza, J., Volpicelli, L.A., Levey, A.I. and Wess, J. (2002) Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knockout mice. J. Neurosci., 22: 1709-1717.